Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Colorectal Neoplasms 9Pancreatic Neoplasms 8Rectal Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Colonic Neoplasms 3Adenocarcinoma Of Esophagus 3Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Neoplasm Metastasis 2Clinical Stage I Gastric Cancer AJCC v8 2Cholangiocarcinoma 2Appendiceal Neoplasms 2Anus Neoplasms 2Uterine Neoplasms 1Tongue Neoplasms 1Sinonasal undifferentiated carcinoma 1Salivary Gland Neoplasms 1Peritoneal Neoplasms 1Paranasal Sinus Neoplasms 1Pancreatic Intraductal Neoplasms 1Pancreatic Adenocarcinoma 1PRETEXT I Hepatoblastoma 1Oropharyngeal Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Metastatic Small Intestinal Adenocarcinoma 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1

Interventions

Capecitabine 41Oxaliplatin 39Fluorouracil 29Leucovorin 23Radiotherapy 21Cetuximab 14Bevacizumab 14Irinotecan 13Nivolumab 12Magnetic Resonance Spectroscopy 11Specimen Handling 9Surgical Procedures, Operative 8Folfox protocol 8Drug Therapy 8pembrolizumab 7Radiotherapy, Intensity-Modulated 7Chemoradiotherapy 7Biopsy 7trifluridine tipiracil drug combination 6Radiation 6tislelizumab 5sintilimab 5regorafenib 5dehydroftorafur 5X-Rays 5Surveys and Questionnaires 5Sigmoidoscopy 5Endoscopy 5Consolidation Chemotherapy 5spartalizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Rectal Neoplasms × dehydroftorafur × 1 year × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

NCT04703101 2026-03-30

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Jonsson Comprehensive Cancer Center

Phase 1 Recruiting
25 enrolled
Gastrointestinal

Rectal Neoplasms

NCT02921256 2025-12-04

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
363 enrolled 16 charts
Gastrointestinal

Rectal Neoplasms

NCT05627635 2025-11-10

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

City of Hope Medical Center

Phase 1/2 Active not recruiting
20 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06780787 2025-06-26

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

City of Hope Medical Center

Phase 2 Recruiting
26 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡